Slynd, Drovelis(drospirenone)
Angeliq, Beyaz, Drospirenone / Ethinyl Estradiol, Drospirenone / Ethinyl Estradiol /, Drovelis, Lo-zumandimine, Loryna, Lydisilka, Melamisa, Nextstellis, Nikki, Safyral, Slynd, Syeda, Tydemy, Yaela, Yasmin, Yaz, Zumandimine (drospirenone) is a small molecule pharmaceutical. Drospirenone was first approved as Yasmin on 2001-05-11. The pharmaceutical is active against mineralocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Drospirenone, Slynd (discontinued: Drospirenone)
CombinationsAngeliq, Beyaz, Drospirenone estradiol, Drospirenone ethinyl estradiol, Drospirenone, ethinyl estradiol levomefolate, Lo-zumandimine, Loryna, Melamisa, Nextstellis, Nikki, Safyral, Syeda, Tydemy, Yaela, Yasmin, Yaz, Zumandimine (discontinued: Drospirenone ethinyl estradiol, Kemeya, Kyra)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Drospirenone
+
Estetrol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NEXTSTELLIS | Mayne Group | N-214154 RX | 2021-04-15 | 1 products, RLD, RS |
Drospirenone
+
Estradiol
Drospirenone
+
Ethinyl estradiol
+
Levomefolate calcium
Drospirenone
+
Ethinyl estradiol
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| angeliq | New Drug Application | 2023-12-08 |
| beyaz | New Drug Application | 2023-05-19 |
| drospirenone and ethinyl estradiol | ANDA | 2025-12-02 |
| drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium | ANDA | 2025-04-14 |
| drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium | NDA authorized generic | 2023-05-19 |
| gianvi | New Drug Application | 2010-11-03 |
| jasmiel | ANDA | 2024-05-14 |
| lo-zumandimine | ANDA | 2023-10-09 |
| loryna | ANDA | 2024-01-10 |
| nextstellis | New Drug Application | 2023-05-11 |
Show 11 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DROSPIRENONE / ESTETROL, NEXTSTELLIS, MAYNE PHARMA | |||
| 2026-04-15 | NCE | ||
DROSPIRENONE, DROSPIRENONE, EXELTIS USA INC | |||
| 2025-06-29 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Drospirenone / Estradiol, Angeliq, Bayer Hlthcare | |||
| 8906890 | 2031-10-22 | DP | |
| Drospirenone, Drospirenone, Exeltis Usa Inc | |||
| 9603860 | 2031-06-28 | U-2553 | |
| 10179140 | 2031-06-28 | U-2553 | |
| 10603281 | 2031-06-28 | U-2553 | |
| 10849857 | 2031-06-28 | DP | U-2553 |
| 10987364 | 2031-06-28 | DP | |
| 11123299 | 2031-06-28 | DP | |
| 11291632 | 2031-06-28 | DP | |
| 11291633 | 2031-06-28 | DP | |
| 11351122 | 2031-06-28 | DP | |
| 11413249 | 2031-06-28 | U-2553 | |
| 11439598 | 2031-06-28 | DP | |
| 11478487 | 2031-06-28 | DP | |
| 11504334 | 2031-06-28 | DP | |
| Drospirenone / Ethinyl Estradiol / Levomefolate Calcium, Beyaz, Bayer Hlthcare | |||
| 8617597 | 2030-02-08 | DP | |
| Drospirenone / Estetrol, Nextstellis, Mayne Pharma | |||
| 7732430 | 2025-03-02 | DP | U-3152 |
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA12: Drospirenone and ethinylestradiol
— G03AA18: Drospirenone and estetrol
— G03AC: Progestogen systemic hormonal contraceptives
— G03AC10: Drospirenone
— G03F: Progestogens and estrogens in combination
— G03FA: Progestogens and estrogens, fixed combinations
— G03FA17: Drospirenone and estrogen
HCPCS
No data
Clinical
Clinical Trials
173 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 9 | 4 | 20 | 4 | 14 | 49 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 2 | 1 | 5 | 8 | 7 | 22 |
| Healthy volunteers/patients | — | — | — | 14 | — | 2 | 1 | — | 17 |
| Syndrome | D013577 | — | — | 1 | — | 4 | 2 | 6 | 13 |
| Premenstrual syndrome | D011293 | — | N94.3 | — | 1 | 3 | 2 | 4 | 10 |
| Dysmenorrhea | D004412 | — | N94.6 | — | 2 | 5 | 2 | 3 | 10 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | 2 | 3 | 1 | 6 |
| Postmenopause | D017698 | — | — | — | 1 | 2 | 1 | 2 | 6 |
| Premenstrual dysphoric disorder | D065446 | — | F32.81 | — | 2 | 1 | 2 | — | 5 |
| Pelvic pain | D017699 | — | — | — | — | — | 3 | 1 | 4 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 4 | — | 2 | 6 |
| Hot flashes | D019584 | — | — | — | — | 3 | — | — | 3 |
| Neural tube defects | D009436 | — | Q00.0 | — | — | 2 | — | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | — | — | 2 |
| Metrorrhagia | D008796 | — | N92.1 | — | — | 1 | — | 1 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | 1 | — | — | 1 |
| Ovulation inhibition | D034445 | — | — | — | — | 1 | — | — | 1 |
| Essential hypertension | D000075222 | — | I10 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 1 | — | — | 3 | 4 |
| Bulimia | D002032 | — | F50.2 | — | 1 | — | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | — | — | — | 1 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | 1 | — | — | — | 1 |
| Binge-eating disorder | D056912 | — | F50.2 | — | 1 | — | — | — | 1 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | 1 | — | — | — | 1 |
| Hormonal contraception | D000080282 | — | — | — | 1 | — | — | — | 1 |
| Prehypertension | D058246 | — | — | — | 1 | — | — | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | — | 1 |
| Emergencies | D004630 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | 1 | 2 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 1 | 2 |
| Area under curve | D019540 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Absorption | D000042 | — | — | 1 | — | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Communicable diseases | D003141 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | — | — | — | — | 3 | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 2 | 2 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | — | 1 | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 1 | 1 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | — | — | — | 1 | 1 |
| Premature menopause | D008594 | — | E28.31 | — | — | — | — | 1 | 1 |
| Chronic pain | D059350 | — | — | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | — | — | — | 1 | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Drospirenone |
| INN | drospirenone |
| Description | Drospirenone is a steroid lactone and a 3-oxo-Delta(4) steroid. It has a role as a contraceptive drug, an aldosterone antagonist and a progestin. |
| Classification | Small molecule |
| Drug class | aldosterone antagonists (spironolactone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@H]3[C@H]([C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C |
Identifiers
| PDB | — |
| CAS-ID | 67392-87-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1509 |
| ChEBI ID | 50838 |
| PubChem CID | 68873 |
| DrugBank | DB01395 |
| UNII ID | N295J34A25 (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C2
NR3C2
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII8)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Drospirenone
+
Estradiol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Drospirenone
+
Ethinyl estradiol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Drospirenone
+
Ethinyl estradiol
+
Levomefolic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,831 documents
View more details
Safety
Black-box Warning
Black-box warning for: Angeliq, Beyaz, Drospirenone and ethinyl estradiol, Drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium, Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium, Jasmiel, Lo-zumandimine, Loryna, Nextstellis, Nikki, Ocella, Safyral, Syeda, Tydemy, Vestura, Yasmin, Yaz, Zarah, Zumandimine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,296 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use